Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$76,178.00-0.96%ETH$2,419.58-2.27%GOLD$4,388.30+1.28%OIL$103.42-2.28%
Smart Investors Daily
RE

NASDAQ · REPL

Replimune Group, Inc.

Healthcare · Biotechnology

$13.03

Down-$0.08 (-0.61%)

Updated Sep 16, 2026, 12:01 PM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
774.6M
P/E ratio
-3.23
Dividend yield
0.00%
52-week range
$1.50 – $16.33
Volume
2.23M
Avg. volume
5.08M

Price performance

REPL price history

1M range · 20 trading sessions · Daily adjusted prices

REPL closed at $13.03 after 20 trading sessions, down 16.37% for the selected period.

Last close
$13.03
Period change
-16.37%
Period low
$12.92
Period high
$15.98
Daily close
View OHLC price history
REPL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$12.98$13.06$12.46$13.032.23M
Sep 14, 2026$12.90$13.645$12.79$13.112.35M
Sep 11, 2026$13.33$13.74$12.40$12.924.09M
Sep 10, 2026$14.47$14.47$13.21$13.243.65M
Sep 9, 2026$14.54$14.76$14.30$14.451.07M
Sep 8, 2026$14.90$14.99$14.61$14.771.5M
Sep 4, 2026$15.22$15.3313$14.80$15.04910.23K
Sep 3, 2026$15.99$16.025$15.02$15.291.35M
Sep 2, 2026$15.65$16.33$15.50$15.981.99M
Sep 1, 2026$15.24$15.71$14.97$15.671.78M
Aug 31, 2026$15.36$15.52$14.90$15.301.7M
Aug 28, 2026$15.402$15.87$15.40$15.502.39M
Aug 27, 2026$15.76$16.15$15.555$15.601.67M
Aug 26, 2026$15.60$15.99$15.045$15.882.38M
Aug 25, 2026$14.63$15.89$14.59$15.803.14M
Aug 24, 2026$14.63$15.04$14.11$14.712.08M
Aug 21, 2026$13.88$14.98$13.81$14.772.97M
Aug 20, 2026$14.55$14.765$13.92$14.054.3M
Aug 19, 2026$15.17$15.64$14.73$14.813.44M
Aug 18, 2026$14.60$15.615$14.50$15.582.25M

Latest REPL news

The latest Smart Investors Daily articles mentioning REPL.

Stock researchCompany · Overview

REPL research

Overview

Company profile and research snapshot.

Company profile

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.67
Implied upside
—
Analysts
—
REPL recent ratings
DateFirmRatingTarget
Aug 26, 2026JP MorganOverweight—
Aug 7, 2026JP MorganOverweight—
Aug 7, 2026WedbushOutperform—
Aug 4, 2026Leerink PartnersOutperform—
Jul 31, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Replimune to Present at the Cantor Global Healthcare Conference 2026

WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be availa

Benzinga · Aug 14, 2026

Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By